Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 48

1.

Characteristics of mitral valve leaflet length in patients with pectus excavatum: A single center cross-sectional study.

Nomura K, Ajiro Y, Nakano S, Matsushima M, Yamaguchi Y, Hatakeyama N, Ohata M, Sakuma M, Nonaka T, Harii M, Utsumi M, Sakamoto K, Iwade K, Kuninaka N.

PLoS One. 2019 Feb 11;14(2):e0212165. doi: 10.1371/journal.pone.0212165. eCollection 2019.

2.

[The Effectiveness of Counseling Using Preventative Informational Sheets with Climate and Environmental Data from Insurance Pharmacies in Preventing Worsened Asthma Symptoms].

Iwade K, Shimoji S, Masaki H, Sakai T, Tanabe K, Goto N, Ohtsu F.

Yakugaku Zasshi. 2019 Mar 1;139(3):475-482. doi: 10.1248/yakushi.18-00205. Epub 2018 Dec 5. Japanese.

3.

Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.

Zannad F, Anker SD, Byra WM, Cleland JGF, Fu M, Gheorghiade M, Lam CSP, Mehra MR, Neaton JD, Nessel CC, Spiro TE, van Veldhuisen DJ, Greenberg B; COMMANDER HF Investigators.

N Engl J Med. 2018 Oct 4;379(14):1332-1342. doi: 10.1056/NEJMoa1808848. Epub 2018 Aug 27.

4.

Contrast-Induced Nephropathy and Oxygen Pretreatment in Patients With Impaired Renal Function.

Sekiguchi H, Ajiro Y, Uchida Y, Jujo K, Iwade K, Tanaka N, Shimamoto K, Tsurumi Y, Kawana M, Hagiwara N.

Kidney Int Rep. 2017 Aug 12;3(1):65-72. doi: 10.1016/j.ekir.2017.08.002. eCollection 2018 Jan.

5.

Effects of vitamin K antagonist on aortic valve degeneration in non-valvular atrial fibrillation patients: Prospective 4-year observational study.

Yamamoto K, Koretsune Y, Akasaka T, Kisanuki A, Ohte N, Takenaka T, Takeuchi M, Yoshida K, Iwade K, Okuyama Y, Hirano Y, Takeda Y, Tsukamoto Y, Kinugasa Y, Nakatani S, Sakamoto T, Iwakura K, Sozu T, Masuyama T; Japanese Aortic Stenosis Study-2 (JASS-2) Investigators.

Thromb Res. 2017 Dec;160:69-75. doi: 10.1016/j.thromres.2017.10.027. Epub 2017 Nov 6.

PMID:
29121522
6.

Ventricular Fibrillation Due to Early Repolarization Syndrome in the Wake of Hypothermia Due to Fulminant Acute Disseminated Encephalomyelitis.

Yazaki K, Ajiro Y, Shimizu K, Mori F, Yagihara N, Sato A, Takahashi T, Iwade K.

Circ J. 2018 Apr 25;82(5):1478-1480. doi: 10.1253/circj.CJ-17-0748. Epub 2017 Sep 20. No abstract available.

7.

Abrupt disruption of remote monitoring transmission as an indicator of safe backup mode.

Ajiro Y, Mori F, Iwade K.

Europace. 2017 Apr 1;19(4):595. doi: 10.1093/europace/euw203. No abstract available.

8.

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators.

N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.

9.

Multiple focal and macroreentrant left atrial tachycardias originating from a spontaneous scar at the contiguous aorta-left atrium area in a patient with hypertrophic cardiomyopathy: a case report.

Yazaki K, Ajiro Y, Mori F, Watanabe M, Tsukamoto K, Saito T, Mizobuchi K, Iwade K.

BMC Cardiovasc Disord. 2017 Jan 17;17(1):29. doi: 10.1186/s12872-016-0448-3.

10.

Myopotential oversensing notified by Lead Integrity Alert in a patient with implantable cardioverter defibrillator with a dedicated bipolar epicardial sensing lead.

Yazaki K, Ajiro Y, Hasegawa S, Watanabe M, Tsukamoto K, Mizobuchi K, Saito T, Mori F, Iwade K.

Clin Case Rep. 2016 Oct 11;4(12):1091-1095. eCollection 2016 Dec.

11.

How Patient-Pharmacist Communication Using the Drug Profile Book Relates to Patient's Behavior regarding Its Use.

Shoji M, Iwade K, Fujii K, Hirota M, Kanou A, Moriya M, Ishii M, Shimoji S, Onda M, Arakawa Y.

Yakugaku Zasshi. 2016;136(10):1427-1431.

12.

Impacts of patient characteristics on the effectiveness of landiolol in AF/AFL patients complicated with LV dysfunction: Subgroup analysis of the J-Land study.

Kinugawa K, Nagai R, Inoue H, Atarashi H, Seino Y, Yamashita T, Shimizu W, Aiba T, Kitakaze M, Sakamoto A, Ikeda T, Imai Y, Daimon T, Fujino K, Nagano T, Okamura T, Hori M; J-Land Investigators.

Adv Ther. 2014 Apr;31(4):426-39. doi: 10.1007/s12325-014-0111-2. Epub 2014 Mar 19. Erratum in: Adv Ther. 2014 May;31(5):577-8.

13.

Edoxaban versus warfarin in patients with atrial fibrillation.

Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators.

N Engl J Med. 2013 Nov 28;369(22):2093-104. doi: 10.1056/NEJMoa1310907. Epub 2013 Nov 19.

14.

CHADS2 and CHA2DS2-VASc scores as bleeding risk indices for patients with atrial fibrillation: the Bleeding with Antithrombotic Therapy Study.

Toyoda K, Yasaka M, Uchiyama S, Iwade K, Koretsune Y, Nagata K, Sakamoto T, Nagao T, Yamamoto M, Gotoh J, Takahashi JC, Minematsu K; Bleeding with Antithrombotic Therapy Study Group.

Hypertens Res. 2014 May;37(5):463-6. doi: 10.1038/hr.2013.150. Epub 2013 Nov 7.

PMID:
24196199
15.

Risk factor profiles, drug usage, and prevalence of aspirin-associated gastroduodenal injuries among high-risk cardiovascular Japanese patients: the results from the MAGIC study.

Uemura N, Sugano K, Hiraishi H, Shimada K, Goto S, Uchiyama S, Okada Y, Origasa H, Ikeda Y; MAGIC Study Group.

J Gastroenterol. 2014 May;49(5):814-24. doi: 10.1007/s00535-013-0839-5. Epub 2013 Jun 12.

16.

Dabigatran for left atrial thrombus.

Morita S, Ajiro Y, Uchida Y, Iwade K.

Eur Heart J. 2013 Sep;34(35):2745. doi: 10.1093/eurheartj/eht148. Epub 2013 May 22. No abstract available.

17.

Oxygen pre-conditioning prevents contrast-induced nephropathy (OPtion CIN Study).

Sekiguchi H, Ajiro Y, Uchida Y, Ishida I, Otsuki H, Hattori H, Arashi H, Kobayashi Y, Jujo K, Yamaguchi J, Ii M, Iwade K, Tanaka N, Shimamoto K, Tsurumi Y, Kawana M, Hagiwara N; Yokohama Medical Center Clinical Research Group.

J Am Coll Cardiol. 2013 Jul 9;62(2):162-163. doi: 10.1016/j.jacc.2013.04.012. Epub 2013 May 1. No abstract available.

18.

Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-Land Study).

Nagai R, Kinugawa K, Inoue H, Atarashi H, Seino Y, Yamashita T, Shimizu W, Aiba T, Kitakaze M, Sakamoto A, Ikeda T, Imai Y, Daimon T, Fujino K, Nagano T, Okamura T, Hori M; J-Land Investigators.

Circ J. 2013;77(4):908-16. Epub 2013 Mar 15.

19.

Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial.

Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L, Alings M, Goto S, Lewis BS, Rosenqvist M, Hanna M, Mohan P, Alexander JH, Diener HC; ARISTOTLE Committees and Investigators.

Lancet Neurol. 2012 Jun;11(6):503-11. doi: 10.1016/S1474-4422(12)70092-3. Epub 2012 May 8. Erratum in: Lancet Neurol. 2012 Dec;11(12):1021.

PMID:
22572202
20.

Rivaroxaban in patients with a recent acute coronary syndrome.

Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM; ATLAS ACS 2–TIMI 51 Investigators.

N Engl J Med. 2012 Jan 5;366(1):9-19. doi: 10.1056/NEJMoa1112277. Epub 2011 Nov 13.

Supplemental Content

Loading ...
Support Center